Episode Details

Anthropic files to go public in one of the most hotly anticipated IPOs of all-time, but it's not without controversy as the Claude-maker warn of an 'existential threat to humanity.' Elsewhere, Novartis narrowly misses net sales estimates but ups its guidance thanks to strong demand for its key cancer and multiple sclerosis drugs. And HSBC shares are under pressure despite a sharp jump in quarterly profit, as a slowdown in its wealth management arm disappoints investors.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.